• Stefan P Renner, Reiner Strick, Peter A Fasching, Sonja Oeser, Peter Oppelt, Andreas Mueller, Matthias W Beckmann, and Pamela L Strissel.
• Department of Gynaecology and Obstetrics, University-Clinic Erlangen, Laboratory for Molecular Medicine, Erlangen, Germany.
• Am. J. Obstet. Gynecol. 2008 Dec 1; 199 (6): 648.e1-9.

ObjectiveUterine benign leiomyomas result from proliferation of a single smooth-muscle cell and their growth is affected by steroid hormones via steroid hormone receptors. This investigation analyzed the +331G/A and the V600L single nucleotide polymorphisms in the progesterone receptor, and correlated their incidence with clinical and tumor parameters as well as disease risk.Study DesignPeripheral blood DNA was analyzed for the frequency of both progesterone receptor single nucleotide polymorphisms in 270 women with uterine leiomyomas compared with 163 control women without uterine leiomyomas.ResultsNo correlation was found for both single nucleotide polymorphisms or the risk for developing myoma; however, statistical significant associations were found for single nucleotide polymorphism genotypes with specific clinical and tumor characteristics, eg, endometriosis, number of live births, menstrual cycle disorder, and leiomyoma focality.ConclusionOur findings support that specific genotypes in the progesterone receptor may be involved in tumor growth and metastasis but not in tumor initiation.

29 keywords...

hide…